EMRELIS (telisotuzumab vedotin-tllv)
ANTINEOPLASTIC MONOCLONAL ANTIBODIES · NON-SQUAMOUS NON-SMALL CELL LUNG CANCER (NSCLC) WITH HIGH C-MET PROTEIN OVEREXPRESSION
ABBOTT
Drug class
Antineoplastic Monoclonal Antibodies
Antineoplastic monoclonal antibodies are a major class of targeted biologic therapeutics designed to bind specific antigens expressed on malignant cells or within the tumor microenvironment. Read more about Antineoplastic Monoclonal Antibodies
29 drugs in this class 21 manufacturers
Drugs in Antineoplastic Monoclonal Antibodies
ARZERRA (ofatumumab)
ANTINEOPLASTIC MONOCLONAL ANTIBODIES · CHRONIC LYMPHOCYTIC LEUKEMIA ·+2
Novartis Pharmaceuticals
Filter & compare in the drug finder →
Opens the drug finder with Antineoplastic Monoclonal Antibodies preselected. Add indication or manufacturer filters there.
Antineoplastic monoclonal antibodies are a major class of targeted biologic therapeutics designed to bind specific antigens expressed on malignant cells or within the tumor microenvironment.
By recognizing defined molecular targets, these agents exert anti-tumor activity through multiple mechanisms, including blocking oncogenic signaling pathways, promoting immune-mediated cytotoxicity, inhibiting tumor angiogenesis, or selectively delivering cytotoxic payloads as antibody-drug conjugates.
Clinically, this drug class plays a central role across diverse oncologic diseases, including hematologic malignancies such as leukemias, lymphomas, and multiple myeloma, as well as numerous solid tumors, including breast, colorectal, lung, and melanoma.
-
nih.gov
Antineoplastic monoclonal antibodies are a major class of targeted biologic therapeutics designed to bind specific antigens expressed on malignant cells or within the tumor microenvironment
-
cancer.gov
Antineoplastic monoclonal antibodies are a major class of targeted biologic therapeutics designed to bind specific antigens expressed on malignant cells or within the tumor microenvironment
-
youtube.com
By recognizing defined molecular targets, these agents exert anti-tumor activity through multiple mechanisms, including blocking oncogenic signaling pathways, promoting immune-mediated cytotoxicity, inhibiting tumor angiogenesis, or selectively delivering cytotoxic payloads as antibody-drug conjugates
-
mayoclinic.org
By recognizing defined molecular targets, these agents exert anti-tumor activity through multiple mechanisms, including blocking oncogenic signaling pathways, promoting immune-mediated cytotoxicity, inhibiting tumor angiogenesis, or selectively delivering cytotoxic payloads as antibody-drug conjugates
-
nih.gov
By recognizing defined molecular targets, these agents exert anti-tumor activity through multiple mechanisms, including blocking oncogenic signaling pathways, promoting immune-mediated cytotoxicity, inhibiting tumor angiogenesis, or selectively delivering cytotoxic payloads as antibody-drug conjugates
-
rxlist.com
Clinically, this drug class plays a central role across diverse oncologic diseases, including hematologic malignancies such as leukemias, lymphomas, and multiple myeloma, as well as numerous solid tumors, including breast, colorectal, lung, and melanoma
Sign in to follow this class
Following a drug class requires a free Physicians Office Resource account.